- Home
- INKT vs ENLV Comparison
INKT vs ENLV Comparison
Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 258.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INKT | ENLV |
|---|---|---|
| Price | $9.46 | $1.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $13.00 |
| AVG Volume (30 Days) | 155.7K | ★ 517.5K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $0.66 |
| 52 Week High | $76.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | INKT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 49.58 |
| Support Level | $6.80 | $0.98 |
| Resistance Level | $12.64 | $1.23 |
| Average True Range (ATR) | 0.86 | 0.07 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 18.70 | 26.23 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.